Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Feasibility Testing of Plant-Based Supplemented Food Products Made With Manitoba Crop Ingredients for Weight Loss

15. September 2026 aktualisiert von: Dylan MacKay, University of Manitoba

The purpose of this study is to advance the development of the WI/CDIC supplemented foods by evaluating the acceptance and feasibility of the supplemented food bars within the Wellness Institute's Weight Loss Clinic program (WLC) or an equivalent weight loss program in Winnipeg or the surrounding area. The main questions it aims to answer are:

  • To determine whether the incorporation of WI/CDIC supplemented foods into the WI weight loss clinic design is feasible.
  • To determine whether weight loss is supported by a plant-based supplemented food.
  • To assess efficacy of the supplemented food by measuring changes in lifestyle behaviours and risk factors for chronic disease compared to non-supplemented food weight loss program members.

Researchers will compare the WLC program plus supplemented food to the WLC program without the supplemented food to evaluate the implementation of the supplemented foods into the WLC.

Participants will follow their WLC program for the initial 16 weeks, and those in the intervention group will begin their supplemented food. Participants will consume one supplemented food bar each day and will record this in the product consumption log.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Detaillierte Beschreibung

This is a pilot evaluation of the feasibility of incorporating the WI/CDIC supplemented food into the WI's newly designed WLC. This study will employ a mixed methods quasi-experimental approach using questionnaires and data collected over the evaluation period. Following consent, participants will be asked to fill out a set of questionnaires, to capture dietary intake, and to wear an activity monitor; to measure diet, physical activity, QOL and sleep before each study meeting. Eligible participants (n=40) will be randomized to intervention (supplemented food) or no intervention. Participants will attend two in-person study visits - one at the initiation and one at the completion of the 16-week weight loss program. Body weight, height, waist circumference, blood pressure and heart rate will be recorded at these two time points as well, as collected through the weight loss clinic program. Participants will also complete an exit questionnaire at the second visit that will include a 9-point hedonic scale to evaluate product acceptability.

Studientyp

Interventionell

Einschreibung (Geschätzt)

40

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

    • Manitoba
      • Winnipeg, Manitoba, Kanada, R2V 3M3
        • Seven Oaks Hospital Chronic Disease Innovation Centre
        • Kontakt:
        • Unterermittler:
          • Dr Rebecca Mollard, PhD

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Male or female, aged 18 years or above
  • Live within the province of MB
  • Ability to give written informed consent in English.
  • Enrolled in the Wellness Institute Weight Loss Clinic or an equivalent, approved weight loss program in Winnipeg or the surrounding area.

Exclusion Criteria:

  • Female participant who is pregnant, lactating or planning pregnancy during the course of the program.
  • Participants with known allergies to the supplemented food ingredients
  • Has an active eating disorder

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: The WLC program plus supplemented food

Participants in weight loss clinic program will consume one supplemented food bar each day and will record this in the product consumption log.

These supplemented foods provide plant-based protein, fibre and fatty acids that have been shown to have health benefits related to chronic disease.

Kein Eingriff: The WLC program only

Participants in the weight loss clinic only.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Feasibility of incorporating the WI/CDIC supplemented foods into the WI weight loss clinic.
Zeitfenster: End of Study (Week 16)

Feasibility will be demonstrated if the following five criteria are met:

  1. Eligibility to randomization ratio is greater than 0.5, calculated as the ratio of individuals within the WI WLC program who were randomized to the trial to the number eligible to participate who were approached to participate.
  2. The percentage of participants who complete the 16-week program in the supplemented food arm is equivalent (plus or minus 10%) or greater than the standard arm.
  3. Follow up of greater than 85% of participant outcomes.
  4. Adherence to the supplemented food intervention calculated by consumption of >75% dispensed products as documented in the Product Consumption Log
  5. Product Acceptability using an Exit Questionnaire consisting of a 9-point hedonic box scale to assess mean acceptability values of 6 or greater (like at least slightly) in 75% or more of the participants.
End of Study (Week 16)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Changes in Body Weight
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Body weight will be measured in kg to the nearest 0.1 kg by an exercise professional.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Waist Circumference
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Waist circumference in cm will be measured to the nearest 0.1 cm at the umbilicus, between the last rib and iliac crest using a fibreglass tape measured by an exercise professional.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in BMI
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Body Mass Index will be calculated using the formula BMI = kg/m2; where kg is the weight in kilograms and m2 is height in metres squared.

At Enrollment (Week 0) and End of Study (Week 16)
Cardiovascular Assessment
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Using the Framingham Risk Score, cardiovascular risk will be calculated based on age, HDL-C, total cholesterol, systolic blood pressure, smoking status, and diabetes status to determine the participant's 10-year risk of cardiovascular disease and identification of metabolic syndrome.

At Enrollment (Week 0) and End of Study (Week 16)
Changes is Quality of Life
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Quality of life will be measured through the SF-36 quality of life questionnaire. The SF-36 measures nine areas: physical functioning, role functioning (emotional), role functioning (physical), energy/fatigue, emotional well-being, social functioning, pain, general health, and health change. A higher score indicates greater levels of quality of life.

At Enrollment (Week 0) and End of Study (Week 16)

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Changes in Systolic Blood Pressure
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Systolic blood pressure in mmHg is measured in triplicate, on the non-dominant arm in a sitting position by an exercise professional using a validated oscillometric blood pressure monitor.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Diastolic Blood Pressure
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Diastolic blood pressure in mmHg is measured in triplicate, on the non-dominant arm in a sitting position by an exercise professional using a validated oscillometric blood pressure monitor.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Heart Rate
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Heart rate in beats per minute is measured in triplicate, on the non-dominant arm in a sitting position by an exercise professional using a validated oscillometric blood pressure monitor.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Physical Activity
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Measured using the International Physical Activity Questionnaire - Short Form - (IPAQ-S)

At Enrollment (Week 0) and End of Study (Week 16)
Change in Physical Activity Behaviour Patterns
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Assessed using total active minutes per day as measured by multi-directional accelerometry for 7 days. Participants will be asked to wear the accelerometer at all times.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake Behaviours
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Dietary intake behaviours will be measured through The Mindful Eating Questionnaire. The Mindful Eating Questionnaire recognizing patterns of overeating or eating in response to stress, boredom, or other emotions. Scoring is based on five categories, which include Awareness (being aware of how food looks, tastes and smells); Distraction (focusing on other things while eating); Disinhibition (eating even when full); Emotional Response (eating in response to sadness or stress); and External Cues (eating in response to environmental cues, such as advertising)

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake Behaviours
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Changes in dietary intake behaviours will be measured through the Three Factor Eating Questionnaire which is comprised of 18 items, measuring uncontrolled eating, restrained eating and emotional eating. The higher the score represents more dependency to cognition, stress or emotion the eating patterns.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Number of Meals
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Number of meals will be captured with a meal being defined as food intake greater than 500 kcal. Dietary intake will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Number of Snacks
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Number of snacks will be captured with a meal being defined as food intake less than 500 kcal. Dietary intake will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Energy
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Energy will be measured in kCals and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Protein
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Protein will be measured in grams and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Fat
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Fat will be measured in grams and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Available Carbohydrates
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Available carbohydrates will be measured in grams and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Fibre
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Fibre will be measured in grams and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Sleep Patterns
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

An ActiGraph activity monitor will be used to measure sleep quality patterns for 7 days, with participants asked to wear the monitor at all times, including when they sleep.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Total Cholesterol
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in High density lipoprotein cholesterol
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Low density lipoprotein cholesterol
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Triglycerides
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Total Cholesterol and High-Density Lipoprotein Cholesterol Ratio
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Hemoglobin A1C
Zeitfenster: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. November 2026

Primärer Abschluss (Geschätzt)

31. Dezember 2027

Studienabschluss (Geschätzt)

31. Dezember 2027

Studienanmeldedaten

Zuerst eingereicht

23. September 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

23. September 2024

Zuerst gepostet (Tatsächlich)

26. September 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

21. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

15. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

De-identified individual participant data (IPD) may be placed in a repository if required by a journal for publication purposes. De-identified IPD may also be requested from the principle investigator.

IPD-Sharing-Zeitrahmen

Data will become available following the publication of the primary results manuscript.

IPD-Sharing-Zugriffskriterien

Researchers who provide a methodologically sound proposal and whose proposed use of the data has been approved by the trial PI.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF
  • ANALYTIC_CODE
  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren